Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Quantum Biopharma Ltd. - Class B Subordinate Voting Shares (NQ:QNTM)

3.100 -0.070 (-2.21%)
Streaming Delayed Price Updated: 10:34 AM EDT, Sep 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 32,827
Open 3.140
Bid (Size) 3.100 (5,000)
Ask (Size) 3.190 (100)
Prev. Close 3.170
Today's Range 3.100 - 3.233
52wk Range 2.070 - 21.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NetworkNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Draws ‘Buy’ Rating on Lucid-MS Potential
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Moves Myelin-Protecting MS Therapy to Phase 2 Development
Via Investor Brand Network

Performance

YTD
-55.8%
-55.8%
1 Month
+1.6%
+1.6%
3 Month
-41.0%
-41.0%
6 Month
-13.9%
-13.9%
1 Year
-81.0%
-81.0%

More News

Read More
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Explores Myelin Protection as New Focus in MS Treatment
Via Investor Brand Network
Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves
Via Investor Brand Network
These stocks are moving in today's pre-market session ↗
Via Chartmill
NetworkNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2
Via Investor Brand Network
News headline image
Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial
From Quantum BioPharma
Via GlobeNewswire
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Receives FDA Clearance to Advance Lucid-MS into Phase 2
Via Investor Brand Network
News headline image
Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis:
From Quantum BioPharma
Via GlobeNewswire
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Two-Pronged Approach to Neurological Health
Via Investor Brand Network
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM)Advances Two-Pronged Approach to Neurological Health
Via Investor Brand Network
NetworkNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances MS Imaging Study with Encouraging Preliminary Results
Via Investor Brand Network
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Executive Outlines Lucid-MS Development Strategy and Commercial Growth Plans
Via Investor Brand Network
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Developing Two-Pronged Attack on Brain Disorders Affecting Millions
Via Investor Brand Network
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Hits Key Study Milestone as Early MS Imaging Data Shows Promising Signal
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Expands Clinical Development of Neuroprotective Therapy
Via Investor Brand Network
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Expands Clinical Development of Neuroprotective Therapy
Via Investor Brand Network
BioMedNewsBreaks — Why Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Is ‘One to Watch’
Via Investor Brand Network
Topics Intellectual Property
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Showcases Unique MS Drug Candidate, Growth Strategy During Executive Podcast
Via Investor Brand Network
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Reaches Key Midpoint Milestone in Multiple Sclerosis Imaging Study
Via Investor Brand Network
NetworkNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in NetworkNewsAudio Editorial on Multiple Sclerosis
Via Investor Brand Network
News headline image
NetworkNewsAudio Announces Audio Press Release (APR) the Advancement of First-in-Class Treatment for Multiple Sclerosis
From NetworkNewsWire
Via GlobeNewswire
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in BioMedWire Editorial on Multiple Sclerosis Treatment
Via Investor Brand Network
News headline image
Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy
From Quantum BioPharma Ltd.
Via GlobeNewswire

Frequently Asked Questions

Is Quantum Biopharma Ltd. - Class B Subordinate Voting Shares publicly traded?
Yes, Quantum Biopharma Ltd. - Class B Subordinate Voting Shares is publicly traded.
What exchange does Quantum Biopharma Ltd. - Class B Subordinate Voting Shares trade on?
Quantum Biopharma Ltd. - Class B Subordinate Voting Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Quantum Biopharma Ltd. - Class B Subordinate Voting Shares?
The ticker symbol for Quantum Biopharma Ltd. - Class B Subordinate Voting Shares is QNTM on the Nasdaq Stock Market
What is the current price of Quantum Biopharma Ltd. - Class B Subordinate Voting Shares?
The current price of Quantum Biopharma Ltd. - Class B Subordinate Voting Shares is 3.100
When was Quantum Biopharma Ltd. - Class B Subordinate Voting Shares last traded?
The last trade of Quantum Biopharma Ltd. - Class B Subordinate Voting Shares was at 09/01/26 10:34 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.